During the confirmation hearing, Republicans raised questions about whether she would withstand political pressure from the Trump administration and health secretary Kennedy Jr., while a Senate ally, Sen. Bill Cassidy, expressed confidence in her stance.

Two key senators presented clear positions: Cassidy supports Schwartz, pointing to changes in CDC vaccine-autism language as a sign of good faith; Sanders plans to vote against Schwartz, citing worries about political interference.

Cassidy’s conversations with Schwartz helped him back her, casting doubt on earlier concerns and helping push the committee toward a near party-line vote.

Measles outbreaks surged in 2026, reaching 2,318 cases through late July across 45 jurisdictions, with the vast majority linked to outbreaks and roughly 7% hospitalized, but no fatalities reported yet.

The report originates from Endpoints News and notes a paywall prompt for full access.

A confirmed CDC director would stabilize ongoing operations—weekly surveillance, vaccine guidance timelines, state-level technical assistance, and staff retention—rather than instantly stopping outbreaks, influencing response over months.

The nomination sits in a broader pattern of Trump nominees for CDC leadership, with another health nominee, Sean Kaufman, advancing alongside Schwartz, as part of ongoing vacancies at HHS.

The piece describes leadership gaps at HHS, including vacancies at the surgeon general and FDA commissioner, amid a broader struggle for stable CDC leadership.

Schwartz would be the third Trump-era nominee for CDC director in 18 months, underscoring ongoing leadership instability at the agency.

(No substantive point provided in this entry.)

This remains a developing, breaking story with updates anticipated as the full Senate votes.

The article is dated July 30, 2026, noting Schwartz’s confirmation hearing occurred on July 15, 2026.